Loading…
Loading…
HBMHF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for HBMHF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HBMHF and 80,000+ other tickers.
See exactly how HBMHF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HBMHF and 80,000+ other tickers.
HBM Holdings Limited is a biopharmaceutical company in the clinical development phase, dedicated to the discovery and advancement of differentiated antibody therapeutics for immunological and oncological disorders. The firm's robust pipeline includes several notable candidates: Batoclimab (HBM9161), a human monoclonal antibody designed to selectively bind to and inhibit the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036), intended to address moderate to severe dry eye disease; HBM7008, a bispecific antibody engineered to engage tumor-associated antigens; and HBM4003, a human…
No recent news available.